Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study.
Identifieur interne : 000C80 ( PubMed/Corpus ); précédent : 000C79; suivant : 000C81Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study.
Auteurs : Aleksandar Sekulic ; Michael R. Migden ; Nicole Basset-Seguin ; Claus Garbe ; Anja Gesierich ; Christopher D. Lao ; Chris Miller ; Laurent Mortier ; Dedee F. Murrell ; Omid Hamid ; Jorge F. Quevedo ; Jeannie Hou ; Edward Mckenna ; Natalie Dimier ; Sarah Williams ; Dirk Schadendorf ; Axel HauschildSource :
- BMC cancer [ 1471-2407 ] ; 2017.
Abstract
In the primary analysis of the ERIVANCE BCC trial, vismodegib, the first US Food and Drug Administration-approved Hedgehog pathway inhibitor, showed objective response rates (ORRs) by independent review facility (IRF) of 30% and 43% in metastatic basal cell carcinoma (mBCC) and locally advanced BCC (laBCC), respectively. ORRs by investigator review were 45% (mBCC) and 60% (laBCC). Herein, we present long-term safety and final investigator-assessed efficacy results in patients with mBCC or laBCC.
DOI: 10.1186/s12885-017-3286-5
PubMed: 28511673
Links to Exploration step
pubmed:28511673Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study.</title><author><name sortKey="Sekulic, Aleksandar" sort="Sekulic, Aleksandar" uniqKey="Sekulic A" first="Aleksandar" last="Sekulic">Aleksandar Sekulic</name><affiliation><nlm:affiliation>Mayo Clinic Scottsdale, 13400 East Shea Boulevard, Scottsdale, AZ, 85259, USA. sekulic.aleksandar@mayo.edu.</nlm:affiliation></affiliation></author><author><name sortKey="Migden, Michael R" sort="Migden, Michael R" uniqKey="Migden M" first="Michael R" last="Migden">Michael R. Migden</name><affiliation><nlm:affiliation>Departments of Dermatology and Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Houston, TX, 77030, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Basset Seguin, Nicole" sort="Basset Seguin, Nicole" uniqKey="Basset Seguin N" first="Nicole" last="Basset-Seguin">Nicole Basset-Seguin</name><affiliation><nlm:affiliation>Service de Dermatologie, Hôpital Saint-Louis, 1 av claude Vellefaux, 75010, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Garbe, Claus" sort="Garbe, Claus" uniqKey="Garbe C" first="Claus" last="Garbe">Claus Garbe</name><affiliation><nlm:affiliation>Studienzentrum Dermatologische Onkologie, Universitätsklinikum Tübingen, Liebermeisterstr. 25, 72074, Tübingen, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Gesierich, Anja" sort="Gesierich, Anja" uniqKey="Gesierich A" first="Anja" last="Gesierich">Anja Gesierich</name><affiliation><nlm:affiliation>Klinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Würzburg, Josef-Schneider-Str. 2, 97080, Würzburg, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Lao, Christopher D" sort="Lao, Christopher D" uniqKey="Lao C" first="Christopher D" last="Lao">Christopher D. Lao</name><affiliation><nlm:affiliation>University of Michigan, 1500 East Medical Center Drive, Ann Arbor, MI, 48109, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Miller, Chris" sort="Miller, Chris" uniqKey="Miller C" first="Chris" last="Miller">Chris Miller</name><affiliation><nlm:affiliation>Department of Dermatology, University of Pennsylvania Medical Center, 3400 Civic Center Boulevard, Philadelphia, PA, 19104, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Mortier, Laurent" sort="Mortier, Laurent" uniqKey="Mortier L" first="Laurent" last="Mortier">Laurent Mortier</name><affiliation><nlm:affiliation>Clinique de Dermatologie, Hôpital Claude Huriez, Inserm U1189, Lille, France.</nlm:affiliation></affiliation></author><author><name sortKey="Murrell, Dedee F" sort="Murrell, Dedee F" uniqKey="Murrell D" first="Dedee F" last="Murrell">Dedee F. Murrell</name><affiliation><nlm:affiliation>Dermatology Department, St George Clinical School, University of New South Wales, Grey Street, Sydney, 2217, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Hamid, Omid" sort="Hamid, Omid" uniqKey="Hamid O" first="Omid" last="Hamid">Omid Hamid</name><affiliation><nlm:affiliation>The Angeles Clinic and Research Institute, 1818 Wilshire Boulevard, Los Angeles, California, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Quevedo, Jorge F" sort="Quevedo, Jorge F" uniqKey="Quevedo J" first="Jorge F" last="Quevedo">Jorge F. Quevedo</name><affiliation><nlm:affiliation>Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Hou, Jeannie" sort="Hou, Jeannie" uniqKey="Hou J" first="Jeannie" last="Hou">Jeannie Hou</name><affiliation><nlm:affiliation>Genentech, Inc., 1 DNA Way, South San Francisco, California, 94080, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Mckenna, Edward" sort="Mckenna, Edward" uniqKey="Mckenna E" first="Edward" last="Mckenna">Edward Mckenna</name><affiliation><nlm:affiliation>Genentech, Inc., 1 DNA Way, South San Francisco, California, 94080, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Dimier, Natalie" sort="Dimier, Natalie" uniqKey="Dimier N" first="Natalie" last="Dimier">Natalie Dimier</name><affiliation><nlm:affiliation>Roche Products Limited, Hexagon Place, 6 Falcon Way, Shire Park, Welwyn Garden City, Hertfordshire, Al7 1TW, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Williams, Sarah" sort="Williams, Sarah" uniqKey="Williams S" first="Sarah" last="Williams">Sarah Williams</name><affiliation><nlm:affiliation>Roche Products Limited, Hexagon Place, 6 Falcon Way, Shire Park, Welwyn Garden City, Hertfordshire, Al7 1TW, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Schadendorf, Dirk" sort="Schadendorf, Dirk" uniqKey="Schadendorf D" first="Dirk" last="Schadendorf">Dirk Schadendorf</name><affiliation><nlm:affiliation>Klinikum für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Essen, Hufelandstrabe 55, 45147, Essen, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Hauschild, Axel" sort="Hauschild, Axel" uniqKey="Hauschild A" first="Axel" last="Hauschild">Axel Hauschild</name><affiliation><nlm:affiliation>Universitätsklinikum Schleswig-Holstein, Schittenhelmstr, 7, D-24 105, Kiel, Germany.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28511673</idno><idno type="pmid">28511673</idno><idno type="doi">10.1186/s12885-017-3286-5</idno><idno type="wicri:Area/PubMed/Corpus">000C80</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000C80</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study.</title><author><name sortKey="Sekulic, Aleksandar" sort="Sekulic, Aleksandar" uniqKey="Sekulic A" first="Aleksandar" last="Sekulic">Aleksandar Sekulic</name><affiliation><nlm:affiliation>Mayo Clinic Scottsdale, 13400 East Shea Boulevard, Scottsdale, AZ, 85259, USA. sekulic.aleksandar@mayo.edu.</nlm:affiliation></affiliation></author><author><name sortKey="Migden, Michael R" sort="Migden, Michael R" uniqKey="Migden M" first="Michael R" last="Migden">Michael R. Migden</name><affiliation><nlm:affiliation>Departments of Dermatology and Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Houston, TX, 77030, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Basset Seguin, Nicole" sort="Basset Seguin, Nicole" uniqKey="Basset Seguin N" first="Nicole" last="Basset-Seguin">Nicole Basset-Seguin</name><affiliation><nlm:affiliation>Service de Dermatologie, Hôpital Saint-Louis, 1 av claude Vellefaux, 75010, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Garbe, Claus" sort="Garbe, Claus" uniqKey="Garbe C" first="Claus" last="Garbe">Claus Garbe</name><affiliation><nlm:affiliation>Studienzentrum Dermatologische Onkologie, Universitätsklinikum Tübingen, Liebermeisterstr. 25, 72074, Tübingen, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Gesierich, Anja" sort="Gesierich, Anja" uniqKey="Gesierich A" first="Anja" last="Gesierich">Anja Gesierich</name><affiliation><nlm:affiliation>Klinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Würzburg, Josef-Schneider-Str. 2, 97080, Würzburg, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Lao, Christopher D" sort="Lao, Christopher D" uniqKey="Lao C" first="Christopher D" last="Lao">Christopher D. Lao</name><affiliation><nlm:affiliation>University of Michigan, 1500 East Medical Center Drive, Ann Arbor, MI, 48109, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Miller, Chris" sort="Miller, Chris" uniqKey="Miller C" first="Chris" last="Miller">Chris Miller</name><affiliation><nlm:affiliation>Department of Dermatology, University of Pennsylvania Medical Center, 3400 Civic Center Boulevard, Philadelphia, PA, 19104, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Mortier, Laurent" sort="Mortier, Laurent" uniqKey="Mortier L" first="Laurent" last="Mortier">Laurent Mortier</name><affiliation><nlm:affiliation>Clinique de Dermatologie, Hôpital Claude Huriez, Inserm U1189, Lille, France.</nlm:affiliation></affiliation></author><author><name sortKey="Murrell, Dedee F" sort="Murrell, Dedee F" uniqKey="Murrell D" first="Dedee F" last="Murrell">Dedee F. Murrell</name><affiliation><nlm:affiliation>Dermatology Department, St George Clinical School, University of New South Wales, Grey Street, Sydney, 2217, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Hamid, Omid" sort="Hamid, Omid" uniqKey="Hamid O" first="Omid" last="Hamid">Omid Hamid</name><affiliation><nlm:affiliation>The Angeles Clinic and Research Institute, 1818 Wilshire Boulevard, Los Angeles, California, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Quevedo, Jorge F" sort="Quevedo, Jorge F" uniqKey="Quevedo J" first="Jorge F" last="Quevedo">Jorge F. Quevedo</name><affiliation><nlm:affiliation>Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Hou, Jeannie" sort="Hou, Jeannie" uniqKey="Hou J" first="Jeannie" last="Hou">Jeannie Hou</name><affiliation><nlm:affiliation>Genentech, Inc., 1 DNA Way, South San Francisco, California, 94080, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Mckenna, Edward" sort="Mckenna, Edward" uniqKey="Mckenna E" first="Edward" last="Mckenna">Edward Mckenna</name><affiliation><nlm:affiliation>Genentech, Inc., 1 DNA Way, South San Francisco, California, 94080, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Dimier, Natalie" sort="Dimier, Natalie" uniqKey="Dimier N" first="Natalie" last="Dimier">Natalie Dimier</name><affiliation><nlm:affiliation>Roche Products Limited, Hexagon Place, 6 Falcon Way, Shire Park, Welwyn Garden City, Hertfordshire, Al7 1TW, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Williams, Sarah" sort="Williams, Sarah" uniqKey="Williams S" first="Sarah" last="Williams">Sarah Williams</name><affiliation><nlm:affiliation>Roche Products Limited, Hexagon Place, 6 Falcon Way, Shire Park, Welwyn Garden City, Hertfordshire, Al7 1TW, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Schadendorf, Dirk" sort="Schadendorf, Dirk" uniqKey="Schadendorf D" first="Dirk" last="Schadendorf">Dirk Schadendorf</name><affiliation><nlm:affiliation>Klinikum für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Essen, Hufelandstrabe 55, 45147, Essen, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Hauschild, Axel" sort="Hauschild, Axel" uniqKey="Hauschild A" first="Axel" last="Hauschild">Axel Hauschild</name><affiliation><nlm:affiliation>Universitätsklinikum Schleswig-Holstein, Schittenhelmstr, 7, D-24 105, Kiel, Germany.</nlm:affiliation></affiliation></author></analytic><series><title level="j">BMC cancer</title><idno type="eISSN">1471-2407</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In the primary analysis of the ERIVANCE BCC trial, vismodegib, the first US Food and Drug Administration-approved Hedgehog pathway inhibitor, showed objective response rates (ORRs) by independent review facility (IRF) of 30% and 43% in metastatic basal cell carcinoma (mBCC) and locally advanced BCC (laBCC), respectively. ORRs by investigator review were 45% (mBCC) and 60% (laBCC). Herein, we present long-term safety and final investigator-assessed efficacy results in patients with mBCC or laBCC.</div></front></TEI><pubmed><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">28511673</PMID><DateCreated><Year>2017</Year><Month>05</Month><Day>17</Day></DateCreated><DateRevised><Year>2017</Year><Month>08</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2407</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>1</Issue><PubDate><Year>2017</Year><Month>May</Month><Day>16</Day></PubDate></JournalIssue><Title>BMC cancer</Title><ISOAbbreviation>BMC Cancer</ISOAbbreviation></Journal><ArticleTitle>Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study.</ArticleTitle><Pagination><MedlinePgn>332</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12885-017-3286-5</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In the primary analysis of the ERIVANCE BCC trial, vismodegib, the first US Food and Drug Administration-approved Hedgehog pathway inhibitor, showed objective response rates (ORRs) by independent review facility (IRF) of 30% and 43% in metastatic basal cell carcinoma (mBCC) and locally advanced BCC (laBCC), respectively. ORRs by investigator review were 45% (mBCC) and 60% (laBCC). Herein, we present long-term safety and final investigator-assessed efficacy results in patients with mBCC or laBCC.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">One hundred four patients with measurable advanced BCC received oral vismodegib 150 mg once daily until disease progression or intolerable toxicity. The primary end point was IRF-assessed ORR. Secondary end points included ORR, duration of response (DOR), progression-free survival, overall survival (OS), and safety.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">At data cutoff (39 months after completion of accrual), 8 patients were receiving the study drug (69 patients in survival follow-up). Investigator-assessed ORR was 48.5% in the mBCC group (all partial responses) and 60.3% in the laBCC group (20 patients had complete response and 18 patients had partial response). ORRs were comparable across patient subgroups, including aggressive histologic subtypes (eg, infiltrative BCC). Median DOR was 14.8 months (mBCC) and 26.2 months (laBCC). Median OS was 33.4 months in the mBCC cohort and not estimable in the laBCC cohort. Adverse events remained consistent with clinical experience. Thirty-three deaths (31.7%) were reported; none were related to vismodegib.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This long-term update of the ERIVANCE BCC trial demonstrated durability of response, efficacy across patient subgroups, and manageable long-term safety of vismodegib in patients with advanced BCC.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">This study was registered prospectively with Clinicaltrials.gov , number NCT00833417 on January 30, 2009.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sekulic</LastName><ForeName>Aleksandar</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Mayo Clinic Scottsdale, 13400 East Shea Boulevard, Scottsdale, AZ, 85259, USA. sekulic.aleksandar@mayo.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Migden</LastName><ForeName>Michael R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Departments of Dermatology and Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Houston, TX, 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Basset-Seguin</LastName><ForeName>Nicole</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Service de Dermatologie, Hôpital Saint-Louis, 1 av claude Vellefaux, 75010, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garbe</LastName><ForeName>Claus</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Studienzentrum Dermatologische Onkologie, Universitätsklinikum Tübingen, Liebermeisterstr. 25, 72074, Tübingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gesierich</LastName><ForeName>Anja</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Klinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Würzburg, Josef-Schneider-Str. 2, 97080, Würzburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lao</LastName><ForeName>Christopher D</ForeName><Initials>CD</Initials><AffiliationInfo><Affiliation>University of Michigan, 1500 East Medical Center Drive, Ann Arbor, MI, 48109, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Chris</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Dermatology, University of Pennsylvania Medical Center, 3400 Civic Center Boulevard, Philadelphia, PA, 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mortier</LastName><ForeName>Laurent</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Clinique de Dermatologie, Hôpital Claude Huriez, Inserm U1189, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murrell</LastName><ForeName>Dedee F</ForeName><Initials>DF</Initials><AffiliationInfo><Affiliation>Dermatology Department, St George Clinical School, University of New South Wales, Grey Street, Sydney, 2217, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamid</LastName><ForeName>Omid</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>The Angeles Clinic and Research Institute, 1818 Wilshire Boulevard, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quevedo</LastName><ForeName>Jorge F</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hou</LastName><ForeName>Jeannie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Genentech, Inc., 1 DNA Way, South San Francisco, California, 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McKenna</LastName><ForeName>Edward</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Genentech, Inc., 1 DNA Way, South San Francisco, California, 94080, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dimier</LastName><ForeName>Natalie</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Roche Products Limited, Hexagon Place, 6 Falcon Way, Shire Park, Welwyn Garden City, Hertfordshire, Al7 1TW, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Roche Products Limited, Hexagon Place, 6 Falcon Way, Shire Park, Welwyn Garden City, Hertfordshire, Al7 1TW, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schadendorf</LastName><ForeName>Dirk</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Klinikum für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Essen, Hufelandstrabe 55, 45147, Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hauschild</LastName><ForeName>Axel</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Universitätsklinikum Schleswig-Holstein, Schittenhelmstr, 7, D-24 105, Kiel, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>ERIVANCE BCC Investigators</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>05</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Cancer</MedlineTA><NlmUniqueID>100967800</NlmUniqueID><ISSNLinking>1471-2407</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2011 Apr 15;17 (8):2502-11</RefSource><PMID Version="1">21300762</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16</RefSource><PMID Version="1">10655437</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2012 Jun 7;366(23):2225-6</RefSource><PMID Version="1">22670909</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Am Acad Dermatol. 1984 Jun;10(6):1043-60</RefSource><PMID Version="1">6736323</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Curr Opin Oncol. 2013 May;25(3):218-23</RefSource><PMID Version="1">23493193</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Dermatol Online J. 2006 Sep 08;12(5):7</RefSource><PMID Version="1">16962022</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer. 1994 Jan 15;73(2):328-35</RefSource><PMID Version="1">8293396</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Am Acad Dermatol. 2015 Jun;72(6):1021-6.e8</RefSource><PMID Version="1">25981002</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Lett. 2005 Jul 28;225(2):181-92</RefSource><PMID Version="1">15978322</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Cancer. 2014 Mar;50(4):774-83</RefSource><PMID Version="1">24412051</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Am Acad Dermatol. 1991 May;24(5 Pt 1):715-9</RefSource><PMID Version="1">1869642</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 1998 Jan 1;391(6662):90-2</RefSource><PMID Version="1">9422511</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Oncologist. 2016 Oct;21(10 ):1218-1229</RefSource><PMID Version="1">27511905</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2015 Jun;16(6):729-36</RefSource><PMID Version="1">25981813</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Res. 1998 May 1;58(9):1798-803</RefSource><PMID Version="1">9581815</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Manag Res. 2013 Jul 31;5:197-203</RefSource><PMID Version="1">23940421</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2012 Jun 7;366(23):2171-9</RefSource><PMID Version="1">22670903</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Natl Cancer Inst. 2000 Feb 2;92 (3):205-216</RefSource><PMID Version="1">28158665</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Skin Cancer. 2011;2011:650258</RefSource><PMID Version="1">21253551</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Skin Cancer. 2011;2011:392151</RefSource><PMID Version="1">21151693</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Epidemiol. 2013 Sep 15;178(6):890-7</RefSource><PMID Version="1">23828250</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2015 Jun;16(6):716-28</RefSource><PMID Version="1">25981810</PMID></CommentsCorrections></CommentsCorrectionsList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Basal cell carcinoma (BCC)</Keyword><Keyword MajorTopicYN="N">Efficacy</Keyword><Keyword MajorTopicYN="N">Long-term</Keyword><Keyword MajorTopicYN="N">Safety</Keyword><Keyword MajorTopicYN="N">Vismodegib</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>12</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>04</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>5</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>5</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>5</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28511673</ArticleId><ArticleId IdType="doi">10.1186/s12885-017-3286-5</ArticleId><ArticleId IdType="pii">10.1186/s12885-017-3286-5</ArticleId><ArticleId IdType="pmc">PMC5433030</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C80 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000C80 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:28511673
|texte= Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:28511673" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |